Exhibit 99.3
S.R. Batliboi & Associates LLP Chartered Accountants | THE SKYVIEW 10 18th Floor, "NORTH LOBBY" Survey No. 83/1, Raidurgam Hyderabad – 500 032, India
Tel: +91 40 6141 6000 |
Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
Review Report to
The Board of Directors
Dr. Reddy’s Laboratories Limited
1. | We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Reddy’s Laboratories Limited (the “Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”), and joint ventures for the quarter and nine months ended December 31, 2021 (the “Statement”) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). |
2. | The Holding Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company’s Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. |
3. | We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. |
We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. | The Statement includes the results of the following entities: |
S. No | Name of the Company Subsidiaries | |
1 | Aurigene Discovery Technologies Limited | |
2 | Cheminor Investments Limited | |
3 | Dr. Reddy’s Bio-Sciences Limited | |
4 | Dr. Reddy’s Farmaceutica Do Brasil Ltda. | |
5 | Dr. Reddy's Laboratories SA | |
6 | Idea2Enterprises (India) Private Limited | |
7 | Imperial Credit Private Limited | |
8 | Industrias Quimicas Falcon de Mexico, S.A.de C.V. | |
9 | Svaas Wellness Limited |
|
S.R. Batliboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB-4295 Regd. Office: 22, Camac Street, Block ‘B’, 3rd Floor, Kolkata-700 016 |
S.R. Batliboi & Associates LLP Chartered Accountants |
S. No | Name of the Company Subsidiaries | |
10 | Aurigene Discovery Technologies (Malaysia) SDN BHD | |
11 | Aurigene Discovery Technologies Inc. | |
12 | Aurigene Pharmaceuticals Services Limited | |
13 | beta Institut gemeinnützige GmbH | |
14 | betapharm Arzneimittel GmbH | |
15 | Chirotech Technology Limited | |
16 | DRL Impex Limited | |
17 | Dr. Reddy’s Laboratories (Australia) Pty. Limited | |
18 | Dr. Reddy’s Laboratories Canada, Inc. | |
19 | Dr. Reddy's Laboratories Chile SPA. | |
20 | Dr. Reddy’s Laboratories (EU) Limited | |
21 | Dr. Reddy’s Laboratories Inc. | |
22 | Dr. Reddy's Laboratories Japan KK | |
23 | Dr. Reddy’s Laboratories Kazakhstan LLP | |
24 | Dr. Reddy’s Laboratories LLC | |
25 | Dr. Reddy's Laboratories Louisiana LLC | |
26 | Dr. Reddy’s Laboratories Malaysia Sdn. Bhd. | |
27 | Dr. Reddy’s Laboratories New York, LLC | |
28 | Dr. Reddy's Laboratories Philippines Inc. | |
29 | Dr. Reddy’s Laboratories (Proprietary) Limited | |
30 | Dr. Reddy's Laboratories Romania S.R.L. | |
31 | Dr. Reddy's Laboratories SAS | |
32 | Dr. Reddy's Laboratories Taiwan Limited | |
33 | Dr. Reddy's Laboratories (Thailand) Limited | |
34 | Dr. Reddy’s Laboratories (UK) Limited | |
35 | Dr. Reddy's Research and Development B.V. | |
36 | Dr. Reddy’s Srl | |
37 | Dr. Reddy’s New Zealand Limited | |
38 | Dr. Reddy's Venezuela, C.A. | |
39 | Dr. Reddy's Laboratories B.V. (Formerly Eurobridge Consulting B.V.) | |
40 | Lacock Holdings Limited | |
41 | OOO Dr. Reddy’s Laboratories Limited | |
42 | OOO DRS LLC | |
43 | Promius Pharma LLC | |
44 | Reddy Holding GmbH | |
45 | Reddy Netherlands B.V. | |
46 | Reddy Pharma Iberia SAU | |
47 | Reddy Pharma Italia S.R.L. | |
48 | Reddy Pharma SAS | |
49 | Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020) | |
50 | Dr. Reddy’s Formulations Limited (from March 11, 2021) | |
51 | Dr. Reddy’s (WUXI) Pharmaceutical Company Limited (liquidated w.e.f. December 13, 2021) | |
Joint ventures | ||
1 | DRES Energy Private Limited | |
2 | Kunshan Rotam Reddy Pharmaceutical Company Limited | |
Other consolidating entities | ||
1 | Cheminor Employees Welfare Trust | |
2 | Dr. Reddy's Employees ESOS Trust | |
3 | Dr. Reddy's Research Foundation |
S.R. Batliboi & Associates LLP Chartered Accountants |
5. | Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. |
For S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004
/s/ Shankar Srinivasan | |
per Shankar Srinivasan | |
Partner | |
Membership No.: 213271 | |
UDIN: 22213271AAAAAQ3817 | |
Place: Hyderabad Date: January 28, 2022 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
DR. REDDY'S LABORATORIES LIMITED
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2021
All amounts in Indian Rupees millions | |||||||||||||||||||||||||||
Quarter ended | Nine months ended | Year ended | |||||||||||||||||||||||||
Sl. | 31.12.2021 | 30.09.2021 | 31.12.2020 | 31.12.2021 | 31.12.2020 | 31.03.2021 | |||||||||||||||||||||
No. | Particulars | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | ||||||||||||||||||||
1 | Revenue from operations | ||||||||||||||||||||||||||
a) Net sales/income from operations | 51,031 | 55,167 | 47,109 | 154,460 | 138,119 | 184,202 | |||||||||||||||||||||
b) License fees and service income | 2,166 | 2,465 | 2,187 | 5,563 | 4,319 | 5,520 | |||||||||||||||||||||
c) Other operating income | 186 | 237 | 123 | 680 | 355 | 753 | |||||||||||||||||||||
Total revenue from operations | 53,383 | 57,869 | 49,419 | 160,703 | 142,793 | 190,475 | |||||||||||||||||||||
2 | Other income | 558 | 2,055 | 705 | 3,692 | 2,088 | 2,914 | ||||||||||||||||||||
3 | Total income (1 + 2) | 53,941 | 59,924 | 50,124 | 164,395 | 144,881 | 193,389 | ||||||||||||||||||||
4 | Expenses | ||||||||||||||||||||||||||
a) Cost of materials consumed | 7,605 | 8,232 | 11,773 | 26,976 | 32,697 | 42,958 | |||||||||||||||||||||
b) Purchase of stock-in-trade | 10,819 | 10,314 | 6,803 | 30,868 | 18,968 | 25,736 | |||||||||||||||||||||
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (277 | ) | 1,730 | (2,199 | ) | (2,400 | ) | (6,291 | ) | (7,905 | ) | ||||||||||||||||
d) Employee benefits expense | 9,563 | 10,104 | 9,157 | 29,132 | 27,369 | 36,299 | |||||||||||||||||||||
e) Depreciation and amortisation expense | 2,942 | 2,941 | 3,112 | 8,722 | 9,200 | 12,288 | |||||||||||||||||||||
f) Impairment of non-current assets | 47 | - | 5,972 | 1,885 | 6,753 | 6,768 | |||||||||||||||||||||
g) Finance costs | 216 | 234 | 188 | 643 | 673 | 970 | |||||||||||||||||||||
h) Selling and other expenses | 13,469 | 13,891 | 12,520 | 41,142 | 35,130 | 47,920 | |||||||||||||||||||||
Total expenses | 44,384 | 47,446 | 47,326 | 136,968 | 124,499 | 165,034 | |||||||||||||||||||||
5 | Profit before tax and before share of equity accounted investees(3 - 4) | 9,557 | 12,478 | 2,798 | 27,427 | 20,382 | 28,355 | ||||||||||||||||||||
6 | Share of profit of equity accounted investees, net of tax | 185 | 247 | 151 | 598 | 301 | 480 | ||||||||||||||||||||
7 | Profit before tax (5+6) | 9,742 | 12,725 | 2,949 | 28,025 | 20,683 | 28,835 | ||||||||||||||||||||
8 | Tax expense/(benefit): | ||||||||||||||||||||||||||
a) Current tax | 1,914 | 1,668 | 1,902 | 4,949 | 6,792 | 8,172 | |||||||||||||||||||||
b) Deferred tax | 735 | 1,099 | 768 | 2,221 | (52 | ) | 1,147 | ||||||||||||||||||||
9 | Net profit after taxes and share of profit of associates (7 - 8) | 7,093 | 9,958 | 279 | 20,855 | 13,943 | 19,516 | ||||||||||||||||||||
10 | Other comprehensive income | ||||||||||||||||||||||||||
a) (i) Items that will not be reclassified subsequently to profit or loss | (1,243 | ) | (101 | ) | 2,803 | (2,587 | ) | 2,984 | 4,026 | ||||||||||||||||||
(ii) Income tax relating to items that will not be reclassified to profit or loss | - | - | - | 293 | - | (220 | ) | ||||||||||||||||||||
b) (i) Items that will be reclassified subsequently to profit or loss | 62 | (137 | ) | 930 | (143 | ) | 1,919 | 1,913 | |||||||||||||||||||
(ii) Income tax relating to items that will be reclassified to profit or loss | (57 | ) | (77 | ) | (1 | ) | 39 | (295 | ) | (319 | ) | ||||||||||||||||
Total other comprehensive income | (1,238 | ) | (315 | ) | 3,732 | (2,398 | ) | 4,608 | 5,400 | ||||||||||||||||||
11 | Total comprehensive income (9 + 10) | 5,855 | 9,643 | 4,011 | 18,457 | 18,551 | 24,916 | ||||||||||||||||||||
12 | Paid-up equity share capital (face value Rs. 5/- each) | 832 | 832 | 831 | 832 | 831 | 832 | ||||||||||||||||||||
13 | Other equity | 175,585 | |||||||||||||||||||||||||
14 | Earnings per equity share (face value Rs. 5/- each) | ||||||||||||||||||||||||||
Basic | 42.75 | 60.03 | 1.68 | 125.74 | 84.07 | 117.67 | |||||||||||||||||||||
Diluted | 42.65 | 59.88 | 1.67 | 125.43 | 83.83 | 117.34 | |||||||||||||||||||||
(Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) |
See accompanying notes to the financial results
DR. REDDY'S LABORATORIES LIMITED |
Segment information | All amounts in Indian Rupees millions | ||||||||||||||||||||||||||
Quarter ended | Nine months ended | Year ended | |||||||||||||||||||||||||
Sl. | 31.12.2021 | 30.09.2021 | 31.12.2020 | 31.12.2021 | 31.12.2020 | 31.03.2021 | |||||||||||||||||||||
No. | Particulars | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | ||||||||||||||||||||
Segment wise revenue and results: | |||||||||||||||||||||||||||
1 | Segment revenue : | ||||||||||||||||||||||||||
a) Pharmaceutical Services and Active Ingredients | 9,016 | 10,187 | 8,841 | 28,183 | 29,361 | 39,284 | |||||||||||||||||||||
b) Global Generics | 44,565 | 47,472 | 40,778 | 133,288 | 115,752 | 154,759 | |||||||||||||||||||||
c) Proprietary Products | 129 | 1,232 | 124 | 1,420 | 280 | 523 | |||||||||||||||||||||
d) Others | 1,289 | 596 | 1,412 | 2,368 | 2,424 | 2,814 | |||||||||||||||||||||
Total | 54,999 | 59,487 | 51,155 | 165,259 | 147,817 | 197,380 | |||||||||||||||||||||
Less: Inter-segment revenue | 1,616 | 1,618 | 1,736 | 4,556 | 5,024 | 6,905 | |||||||||||||||||||||
Total revenue from operations | 53,383 | 57,869 | 49,419 | 160,703 | 142,793 | 190,475 | |||||||||||||||||||||
2 | Segment results: | ||||||||||||||||||||||||||
Gross profit from each segment | |||||||||||||||||||||||||||
a) Pharmaceutical Services and Active Ingredients | 1,641 | 2,169 | 1,776 | 5,444 | 6,927 | 9,444 | |||||||||||||||||||||
b) Global Generics | 25,732 | 26,990 | 23,454 | 76,440 | 68,665 | 91,111 | |||||||||||||||||||||
c) Proprietary Products | 129 | 1,232 | 100 | 1,406 | 244 | 482 | |||||||||||||||||||||
d) Others | 1,114 | 397 | 1,211 | 1,817 | 1,880 | 2,058 | |||||||||||||||||||||
Total | 28,616 | 30,788 | 26,541 | 85,107 | 77,716 | 103,095 | |||||||||||||||||||||
Less: Selling and other un-allocable expenditure/(income), net | 18,874 | 18,063 | 23,592 | 57,082 | 57,033 | 74,260 | |||||||||||||||||||||
Total profit before tax | 9,742 | 12,725 | 2,949 | 28,025 | 20,683 | 28,835 |
Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.
Segmental capital employed
As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.
Notes:
1 | These results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended. |
2 | In September 2021, the Company completed the sale of its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BioDelivery Sciences International, Inc. An amount of Rs. 1,084 million is included under the head “License fee and service income” and this pertains to the Company’s Proprietary Products segment. |
3 | Included in "Other income" for the quarter ended 30 September 2021 is Rs. 1,064 million representing the profit on sale of intangible asset, E7777 (anti-cancer agent) to Citius Pharmaceuticals, Inc. This transaction pertains to the Company’s Proprietary Products segment. |
4 | On 14 June 2021, the Company received the arbitration decision and award in favour of Hatchtech Pty Limited regarding the Civil Litigation and Arbitration relating to the acquisition of the product Xeglyze®. The award required the Company to pay an amount of Rs. 3,401 million (U.S.$ 46.25 million) towards milestone payments, interest, and fees. As the Company was carrying only Rs. 1,471 million (U.S.$ 20 million) as the provision towards this litigation, an additional expense of Rs. 1,930 million (U.S.$ 26.25 million) [Rs. 1,838 million (U.S.$ 25 million) as "Impairment of non-current assets" and Rs. 92 million (U.S.$ 1.25 million) as "selling and other expenses"] was recognized during the quarter ended 30 June 2021. The said expense forms part of the Company’s Proprietary Products segment. |
5 | During the year ended 31 March 2021, there were significant changes to the market conditions for certain of the products forming part of Company’s Global Generics and Proprietary Products segments. The changes include the launch by competitor of generic version of the product, decrease in the market potential of products primarily due to higher than expected price erosion and increased competition, and higher than expected value erosion. Due to these adverse market developments, the Company recorded an impairment loss of: |
- Rs. 3,180 million relating to ethinyl estradiol / ethenogestral vaginal ring (a generic equivalent to NuvaRing®);
- Rs. 1,587 million relating to saxagliptin and metformin (generic version of Kombiglyze-XR) and phentermine and topiramate (generic version of Qsymia®);
- Rs. 1,471 million relating to Xeglyze®;
- Rs. 484 million relating to other intangible assets.
Further, an amount of Rs. 46 million has been recognised as impairment of property, plant and equipment.
6 | Tax expense for the year ended 31 March 2021 includes the following: |
- Rs. 1,012 million of benefit, in the quarter ended 30 Septmeber 2020, on account of recognition of deferred tax asset consequent to a planned restructuring activity between the Group companies; and
- Rs. 627 million of expense, in the quarter ended 31 March 2021, on account of de recognition of deferred tax asset due to non-availability of depreciation on goodwill pursuant to an amendment to section 2(11) of the Income Tax Act in the Finance Act, 2021.
7 | During the quarter ended 31 December 2020, the Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire, certain brands in various Emerging Market countries for a total consideration of Rs. 1,516 million. The said transaction was accounted for as an acquisition of product related intangibles, and pertains to Company's Global Generics segment. |
8 | On 10 June 2020, the Company completed the acquisition of select divisions of Wockhardt Limited's branded generics business in India and the territories of Nepal, Sri Lanka, Bhutan and Maldives. The business comprises a portfolio of 62 brands in multiple therapy areas, such as respiratory, neurology, venous malformations, dermatology, gastroenterology, pain, and vaccines. This entire portfolio has been transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh, and employees. During the quarter ended 30 September 2020, the Company completed the purchase price allocation. The fair value of consideration transferred is Rs.16,115 million. The Company recognised Rs. 373 million, Rs. 14,888 million and Rs. 530 million towards property, plant and equipment, intangible assets, and goodwill, respectively. The acquisition pertains to Company's Global Generics segment. |
DR. REDDY'S LABORATORIES LIMITED |
9 | The Company has commenced a detailed investigation into an anonymous complaint received in September 2020. The complaint alleges that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. A U.S. law firm is conducting the investigation at the instruction of a committee of the Company’s Board of Directors. The Company has disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. On 6 July 2021 the Company received a subpoena from the SEC for the production of documents pertaining to certain CIS geographies, and the Company has been responding to the same. |
During the quarter ended 30 September 2021, the Company shared the report with respect to one jurisdiction with the SEC/DOJ. In the current quarter the Company finalized the reports with respect to certain other countries which will be presented to the SEC/DOJ in due course. The investigation is ongoing, and the Company is complying with its listing obligations as it relates to updating the regulatory agencies. While the findings from the aforesaid investigations could result in government enforcement actions against the Company in the United States and/or foreign jurisdictions, which can lead to civil and criminal sanctions under relevant laws, the outcome are not reasonably ascertainable at this time. The Company is also in the process of reviewing its Compliance Program including controls in relation to compliance and implement appropriate enhancements, if any.
10 | India’s Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Company will assess the impact of this Code and the rules thereunder when they come into effect. |
11 | The Company considered the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these interim financial results. Based on its judgments, estimates and assumptions, including sensitivity analysis, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. |
The Company will continue to closely monitor any material changes to future economic conditions.
12 | The unaudited results were reviewed by the Audit Committee of the Board on 27 January 2022 and approved by the Board of Directors of the Company at their meeting held on 28 January 2022. |
13 | The results for the quarter and nine months ended 31 December 2021 were subject to a "Limited Review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon. |
Place: Hyderabad Date: 28 January 2022
| By order of the Board For Dr. Reddy's Laboratories Limited
G V Prasad Co-Chairman & Managing Director
|